SG Austria, Nuvilex use live cell encapsulation technology and treat diabetes in animal model

Nuvilex, Inc. (OTCQB:NVLX) announced today their affiliate SG Austria and partners have successfully treated diabetes in an established, recognized animal model utilizing live encapsulated cells.

The introduced cells responded to elevated blood sugar levels by producing insulin, alleviating the symptoms of diabetes. Moreover, encapsulated cells remained viable and responsive for many months.

These data, as well as previously published results, show it is feasible to overcome the basis for diabetes by implanting encapsulated, insulin-producing cells and pave the way for future clinical trials of encapsulated cells as a means to continuously regulate blood glucose for months, eliminating the need for daily glucose assessment and insulin injections. Such treatment would represent a more natural means of providing insulin to patients that mimics the body's own production, thereby maintaining healthy blood glucose levels.

Diabetes long term effects include kidney failure, amputations, blindness, heart disease and stroke. The World Health Organization (WHO) reports 346 million people worldwide have diabetes and 4 million deaths occur each year as a result. WHO believes, without intervention, these numbers will double by 2030. November 14^th was World Diabetes Day to raise diabetes awareness by The International Diabetes Federation (IDF) and WHO, marking Frederick Banting's birthday, who in 1922 with Charles Best, were influential in insulin's discovery.

IDF and WHO report more than $378 Billion USD/per year are spent on diabetes treatment, predicting it to be more than $490 billion by 2030. Nuvilex is hoping through this treatment to provide better patient outcomes and acquire a proportionate share of this market in the coming years.

Dr. Robert Ryan, President and CEO of Nuvilex stated, "We look forward to the day when people will no longer have to rely on daily insulin injections. Our goal is for patients to receive encapsulated live cell treatments at most every 3 to 6 months, dramatically changing their lives. I believe investors will continue to appreciate the cutting edge technology and recognize us as an innovative leader in the biotechnology and clinical treatment arenas. "